This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsByotrol (BYOT) 주식 개요Develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally. 자세히 보기BYOT 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성5/6배당0/6위험 분석지난 5년간 매년 수익이 39.6% 감소했습니다.의미 있는 시가총액이 없습니다(£454K)지난 3개월 동안 주가 변동성이 UK 시장과 비교했을 때 매우 높았습니다.모든 위험 점검 보기BYOT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.00190.9% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m10m2016201920222025202620282031Revenue UK£4.3mEarnings UK£406.5kAdvancedSet Fair ValueView all narrativesByotrol plc 경쟁사VersarienSymbol: AIM:VRSMarket cap: UK£601.0kSymphony Environmental TechnologiesSymbol: AIM:SYMMarket cap: UK£17.7mSolvonis TherapeuticsSymbol: LSE:SVNSMarket cap: UK£16.7mHardideSymbol: AIM:HDDMarket cap: UK£39.4m가격 이력 및 성과Byotrol 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£0.00152주 최고가UK£0.02652주 최저가UK£0.0005베타-0.511개월 변동-33.33%3개월 변동-84.00%1년 변동-94.12%3년 변동-98.58%5년 변동-95.74%IPO 이후 변동-99.66%최근 뉴스 및 업데이트공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United KingdomReported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Nov 15Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£5.40m to UK£4.70m. Forecast losses increased from -UK£0.001 to -UK£0.002 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 10% next year. Consensus price target of UK£0.045 unchanged from last update. Share price fell 32% to UK£0.0065 over the past week.New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£4.09m market cap, or US$5.10m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year). Share price has been volatile over the past 3 months (7.6% average weekly change).공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.97m market cap, or US$4.84m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Share price has been volatile over the past 3 months (7.2% average weekly change).더 많은 업데이트 보기Recent updates공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United KingdomReported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Nov 15Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£5.40m to UK£4.70m. Forecast losses increased from -UK£0.001 to -UK£0.002 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 10% next year. Consensus price target of UK£0.045 unchanged from last update. Share price fell 32% to UK£0.0065 over the past week.New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£4.09m market cap, or US$5.10m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year). Share price has been volatile over the past 3 months (7.6% average weekly change).공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.97m market cap, or US$4.84m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Share price has been volatile over the past 3 months (7.2% average weekly change).공시 • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.공시 • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.공시 • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to fall by 20% p.a. on average during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 144 percentage points per year, which is a significant difference in performance.New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.9m).New Risk • Jun 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.8m).공시 • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.Reported Earnings • Dec 12First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 18Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021).Reported Earnings • Aug 31Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Price Target Changed • Apr 27Price target increased to UK£0.11Up from UK£0.10, the current price target is provided by 1 analyst. New target price is 273% above last closing price of UK£0.029. Stock is down 60% over the past year. The company posted earnings per share of UK£0.0022 last year.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Dec 08With EPS Growth And More, Byotrol (LON:BYOT) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.분석 기사 • Apr 07If You Like EPS Growth Then Check Out Byotrol (LON:BYOT) Before It's Too LateLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...분석 기사 • Feb 18Here's Why We Don't Think Byotrol's (LON:BYOT) Statutory Earnings Reflect Its Underlying Earnings PotentialIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...분석 기사 • Jan 28Is Byotrol plc's (LON:BYOT) Recent Performance Tethered To Its Attractive Financial Prospects?Byotrol's (LON:BYOT) stock up by 3.4% over the past three months. Given its impressive performance, we decided to study...분석 기사 • Jan 07Here's Why We Think Byotrol (LON:BYOT) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...분석 기사 • Dec 16How Much is Byotrol's (LON:BYOT) CEO Getting Paid?David Traynor has been the CEO of Byotrol plc ( LON:BYOT ) since 2013, and this article will examine the executive's...Reported Earnings • Dec 11First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.분석 기사 • Nov 25Byotrol plc's (LON:BYOT) P/E Is On The MarkWith a price-to-earnings (or "P/E") ratio of 75.8x Byotrol plc (LON:BYOT) may be sending very bearish signals at the...Reported Earnings • Oct 14Full year earnings released - EPS UK£0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue and earnings beat expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Earnings per share (EPS) also surpassed estimates at UK£0.0008 Revenue is forecast to grow 89% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.주주 수익률BYOTGB ChemicalsGB 시장7D-20.0%5.8%2.5%1Y-94.1%8.7%19.4%전체 주주 수익률 보기수익률 대 산업: BYOT은 지난 1년 동안 8.7%의 수익을 기록한 UK Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: BYOT은 지난 1년 동안 19.4%를 기록한 UK 시장보다 저조한 성과를 냈습니다.주가 변동성Is BYOT's price volatile compared to industry and market?BYOT volatilityBYOT Average Weekly Movement66.3%Chemicals Industry Average Movement7.9%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%안정적인 주가: BYOT의 주가는 지난 3개월 동안 UK 시장보다 변동성이 컸습니다.시간에 따른 변동성: BYOT의 주간 변동성은 지난 1년간 34%에서 66%로 증가했습니다.회사 소개설립직원 수CEO웹사이트200536David Traynorbyotrolplc.com더 보기Byotrol plc 기초 지표 요약Byotrol의 순이익과 매출은 시가총액과 어떻게 비교됩니까?BYOT 기초 통계시가총액UK£453.89k순이익 (TTM)-UK£1.85m매출 (TTM)UK£4.38m0.1x주가매출비율(P/S)-0.2x주가수익비율(P/E)BYOT는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표BYOT 손익계산서 (TTM)매출UK£4.38m매출원가UK£2.52m총이익UK£1.86m기타 비용UK£3.72m순이익-UK£1.85m최근 보고된 실적Sep 30, 2023다음 실적 발표일해당 없음주당순이익(EPS)-0.0041총이익률42.51%순이익률-42.33%부채/자본 비율19.7%BYOT의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/30 05:44종가2024/04/30 00:00수익2023/09/30연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Byotrol plc는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David BuxtonCavendishAndrew Murray DarleyCavendishStephen McGarryCavendish1명의 분석가 더 보기
공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United Kingdom
Reported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Nov 15Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£5.40m to UK£4.70m. Forecast losses increased from -UK£0.001 to -UK£0.002 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 10% next year. Consensus price target of UK£0.045 unchanged from last update. Share price fell 32% to UK£0.0065 over the past week.
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£4.09m market cap, or US$5.10m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year). Share price has been volatile over the past 3 months (7.6% average weekly change).
공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.97m market cap, or US$4.84m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Share price has been volatile over the past 3 months (7.2% average weekly change).
공시 • Mar 28Byotrol plc, Annual General Meeting, Apr 22, 2024Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United Kingdom
Reported Earnings • Dec 09First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023)First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Nov 15Consensus revenue estimates fall by 13%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£5.40m to UK£4.70m. Forecast losses increased from -UK£0.001 to -UK£0.002 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 10% next year. Consensus price target of UK£0.045 unchanged from last update. Share price fell 32% to UK£0.0065 over the past week.
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£4.09m market cap, or US$5.10m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year). Share price has been volatile over the past 3 months (7.6% average weekly change).
공시 • Nov 14Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million.
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.97m market cap, or US$4.84m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Share price has been volatile over the past 3 months (7.2% average weekly change).
공시 • Sep 27Byotrol plc Announces Chief Executive Officer ChangesByotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed.
공시 • Sep 08Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation.
공시 • Aug 30Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human HealthcareByotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection.
Reported Earnings • Jul 31Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022)Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to fall by 20% p.a. on average during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 144 percentage points per year, which is a significant difference in performance.
New Risk • Jun 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.9m).
New Risk • Jun 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.8m).
공시 • May 25Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal ClaimsByotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.
Reported Earnings • Dec 12First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 18Full year 2022 earnings releasedFull year 2022 results: Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021).
Reported Earnings • Aug 31Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021)Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Price Target Changed • Apr 27Price target increased to UK£0.11Up from UK£0.10, the current price target is provided by 1 analyst. New target price is 273% above last closing price of UK£0.029. Stock is down 60% over the past year. The company posted earnings per share of UK£0.0022 last year.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Dec 08With EPS Growth And More, Byotrol (LON:BYOT) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Aug 21Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
분석 기사 • Apr 07If You Like EPS Growth Then Check Out Byotrol (LON:BYOT) Before It's Too LateLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
분석 기사 • Feb 18Here's Why We Don't Think Byotrol's (LON:BYOT) Statutory Earnings Reflect Its Underlying Earnings PotentialIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
분석 기사 • Jan 28Is Byotrol plc's (LON:BYOT) Recent Performance Tethered To Its Attractive Financial Prospects?Byotrol's (LON:BYOT) stock up by 3.4% over the past three months. Given its impressive performance, we decided to study...
분석 기사 • Jan 07Here's Why We Think Byotrol (LON:BYOT) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
분석 기사 • Dec 16How Much is Byotrol's (LON:BYOT) CEO Getting Paid?David Traynor has been the CEO of Byotrol plc ( LON:BYOT ) since 2013, and this article will examine the executive's...
Reported Earnings • Dec 11First half 2021 earnings released: EPS UK£0.002The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
분석 기사 • Nov 25Byotrol plc's (LON:BYOT) P/E Is On The MarkWith a price-to-earnings (or "P/E") ratio of 75.8x Byotrol plc (LON:BYOT) may be sending very bearish signals at the...
Reported Earnings • Oct 14Full year earnings released - EPS UK£0.00077Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year.
Analyst Estimate Surprise Post Earnings • Oct 14Annual earnings released: Revenue and earnings beat expectationsAnnual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Earnings per share (EPS) also surpassed estimates at UK£0.0008 Revenue is forecast to grow 89% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
